Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melanoma Antigen Family C1 (MAGEC1)
- Target
- MAGEC1
- Molecular classification
- Cancer/testis antigen, Tumor-specific antigen, Protein-coding gene
01
Overview
Melanoma antigen family C1 (MAGEC1) is a cancer-testis antigen expressed in a variety of tumors but largely silent in normal somatic tissues, with the exception of the testis. It contains unique N-terminal repetitive sequences and is significantly longer than other MAGE family members. Its aberrant expression in cancers like melanoma and multiple myeloma is often associated with increased cell proliferation and poor clinical outcomes. MAGEC1 is a target for cancer immunotherapy due to its restricted expression profile.
- Other names
- CT7CT7.1Cancer/testis antigen 7.1MAGE-C1
02
Mechanism of action
As a cancer-testis antigen, MAGEC1's expression is largely restricted to tumors and testicular tissue, making it an attractive target for cancer immunotherapy. Current strategies aim to elicit a cytotoxic T cell response specifically against MAGEC1-expressing tumor cells.
03
Biological functions
Immune responseCell proliferationTumorigenesis
04
Disease associations
MelanomaMultiple myelomaUterine adnexa cancerNon-Hodgkin's lymphoma
05
Safety considerations
Potential for off-target effects in testicular tissue must be considered during immunotherapy development.Immune-related adverse events are a concern for immunotherapies targeting MAGEC1.
06
Biomarkers
MAGEC1 expression levels can be used as a biomarker for patient stratification and monitoring treatment response in cancers like multiple myeloma.
Beyond the preview
Go deeper on Melanoma Antigen Family C1 (MAGEC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melanoma Antigen Family C1 (MAGEC1).